Topics:

Emend Gets Expanded FDA Approval for Preventing PONV

Emend Gets Expanded FDA Approval for Preventing PONV

WHITEHOUSE STATION, New Jersey—Merck & Co.'s antiemetic Emend (aprepitant) has been granted expanded approval by the FDA to prevent postoperative nausea and vomiting (PONV). Emend, a substance P/neurokinin 1 (NK-1) receptor antagonist, works through a mechanism distinct from that of the 5-HT3 receptor antagonists. Approval was based on two randomized double-blind studies of 1,658 patients undergoing open abdominal surgery. Emend was previously approved for the prevention of chemotherapy-induced nausea and vomiting.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.